| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology*
and
Oncology,
The Johns Hopkins Medical
Institutions, Baltimore, Maryland
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
One immediate goal would be a dissection of the nature of the host stromal response to invasive neoplasm. Recently, new insights into the patterns of gene expression associated with the process of tumor invasion were provided by Ryu and colleagues,1 who demonstrated a cluster of invasion-specific genes in pancreatic cancer using hierarchical clustering and principal component analysis of data from serial analysis of gene expression (SAGE). With this approach, 74 genes were identified that were specifically expressed within tissue specimens of invasive pancreatic cancer, but not within passaged pancreatic cancer cell lines. These invasive tissue-specific genes were thought to primarily reflect the gene expression of the host desmoplastic response within pancreatic cancers that would not be represented in SAGE libraries prepared from cultured pancreatic cell lines. These invasive tissue-specific genes represented many categories of cellular function, including genes associated with extracellular matrix remodeling, angiogenesis, immune responses, and entrapped parenchymal cells. However, because the spatial localization of gene expression was not determined for these tags, their cellular origin within the primary tumor remained unclear (neoplastic epithelium, vasculature, or stromal cells), as did their potential roles within the process of tumor invasion.
We present a set of primary pancreatic cancers studied with in situ hybridization for each of a panel of genes previously found to be highly expressed in invasive pancreatic cancer tissues.1 First, we sought to determine whether these invasive tissue-specific genes are expressed by the tumor, the host, or both; second, we attempted to determine whether spatially defined regions of invasive tumor or desmoplastic stroma might have unique expression profiles within the invasive process; and third, we sought to determine whether any clues to possible communication between the tumor and host response exist (ie, products produced by one compartment that may bind surface receptors of the other).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
Samples of bulk tumor (0.5 g) from two pancreaticoduodenectomy specimens were collected from patients undergoing Whipple resections for infiltrating duct adenocarcinoma of the pancreas. In each case, specimens of bulk tumor were harvested within 10 minutes of resection from the patient and snap-frozen in liquid nitrogen before storage at -80°C. Hematoxylin and eosin-stained sections of the frozen tissue were examined to confirm the presence of infiltrating adenocarcinoma within the section. For additional archival studies of gene expression in invasive pancreatic cancer, formalin-fixed paraffin-embedded tissue blocks from pancreaticoduodenectomy specimens (Whipple resections) from six patients with infiltrating duct adenocarcinoma of the pancreas were collected from the files of The Johns Hopkins Hospital. In each case, clinicopathological information was obtained from the surgical pathology files of The Johns Hopkins Hospital, as well as from the patients’ clinical records. The project adhered to a protocol approved by our institutional review board.
SAGE Analysis of Pancreatic Cancer
The invasion-specific gene cluster identified by SAGE was obtained from previously published work.1 SAGE was performed as described by Zhang and colleagues3 and Zhou and colleagues,4 with principal component analysis and cluster analysis of the data performed by Ryu and colleagues1 as recently described.
Preparation of Riboprobes
To generate riboprobes for use in in situ hybridization of the genes of interest, DNA templates were generated by polymerase chain reaction with incorporation of a T7 promoter into the antisense or sense primer.5,6 After phenol:chloroform purification of amplified DNA, 200 ng of the DNA templates were used to generate either antisense or sense riboprobes by in vitro transcription with digoxigenin-labeling reagents and T7 polymerase according to the manufacturer’s protocol (Roche Diagnostics, Indianapolis, IN).
Nonradioactive in Situ Hybridization of Fresh-Frozen and Paraffin Sections
In situ hybridization of fresh-frozen tissues were performed following the methods described by St. Croix and colleagues.7 Frozen tissues were sectioned at 5-µm thickness at -20°C onto silylated RNase-free microscope slides (CEL Associates, Houston, TX) before fixation in 4% paraformaldehyde/phosphate-buffered saline (PBS) for 1 hour. Next, sections were digested in 0.025% w/v pepsin in 0.2 N HCl for 5 minutes at 37°C, followed by two washes in PBS, and incubation in 5x standard saline citrate (0.75 mol/L sodium chloride and 0.075 mol/L sodium citrate) for 10 minutes. Tissue sections were prehybridized in mRNA hybridization buffer (DAKO, Carpinteria, CA) for 1 hour at 55°C, followed by hybridization overnight at 55°C with 200 ng/ml of antisense or sense riboprobe in mRNA hybridization buffer. The following day, sections were washed in 2x standard saline citrate at 45°C, followed by incubation with a 1/35 dilution of RNase A cocktail (Ambion, Austin, TX) in 10 mmol/L Tris, 500 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic acid, pH 7.5, for 1 hour at 37°C. Next, slides were washed twice in 2x standard saline citrate/50% formamide at 55°C, followed by one wash at 0.08x standard saline citrate also at 55°C. For signal amplification, a horseradish peroxidase-conjugated rabbit anti-digoxigenin antibody (DAKO) was used to catalyze the deposition of biotinyl-tyramide (GenPoint kit, DAKO). Secondary amplification of the signal was achieved by adding horseradish-peroxidase rabbit anti-biotin (DAKO), biotin-tyramide, and then alkaline-phosphatase rabbit anti-biotin (DAKO). Signal was detected with the alkaline-phosphatase substrate Fast Red TR/Napthol AS-MX (Sigma, St. Louis, MO), and the tissue counterstained in hematoxylin for 1 minute.
For formalin-fixed, paraffin-embedded tissues, the above protocol was modified according to the methods described by Kadkol and colleagues8 to optimize conditions. Briefly, sections were deparaffinized in xylene for 5 minutes, followed by hydration in graded ethanols for 5 minutes each. Next, sections were digested in a 10-µg/ml dilution of Proteinase K at 37°C for 30 minutes, followed by hybridization overnight at 55°C with a 200 ng/ml dilution of antisense or sense riboprobes in mRNA hybridization buffer. The following day, sections were serially washed and incubated with RNase A in the same manner as described for fresh-frozen sections, but signal amplification was achieved by incubation of sections with biotinyl-tyramide, followed by secondary streptavidin complex (GenPoint kit, DAKO). The final signal was developed with diaminobenzidine chromagen (GenPoint kit, DAKO).
Histological Evaluation of Tissue Sections
In situ hybridization labeling of mRNA expression in samples of fresh-frozen or paraffin-embedded pancreatic carcinoma was evaluated by three of the authors (CID, RHH, and SEK) with agreement in all cases examined. For each case of infiltrating duct carcinoma, the labeling pattern obtained after in situ hybridization was evaluated for the presence or absence of gene expression individually within the neoplastic epithelium, tumor stroma, and vasculature. In those cases with positive expression noted of the tumor stroma, gene expression was scored as occurring within the entire stromal region of the tumor, or in the stroma immediately adjacent to tumor epithelium.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
As described by Ryu and colleagues,1 hierarchical cluster analysis and principal component analysis were applied to SAGE data of both primary invasive tumors and passaged cell lines representing carcinomas of the colon and pancreas. This approach identified a gene cluster specific for invasive pancreatic cancer tissues.1 A total of 90 tags were identified in this cluster, 74 that matched known transcripts, representing the invasion-specific genes of pancreatic cancer tissues. This cluster is not to be confused with other commonly recognized gene clusters, such as tumor-specific genes (those genes expressed in both neoplastic epithelium derived from invasive cancers and in passaged cancer cell lines), or in tissue-specific genes (those genes expressed in normal tissue, site-matched invasive carcinomas, and passaged cell lines derived from such carcinomas).
Invasive pancreatic cancers represent an aggregate of diverse cell
types, such as invasive neoplastic epithelial cells, fibroblasts,
inflammatory cells, smooth muscle cells, endothelial cells, and cells
of residual nonneoplastic pancreatic parenchyma. Thus, the precise
cellular origin of these transcripts cannot be determined without
additional study. To define the cellular origin and patterns of
expression of these genes associated with the process of tissue
invasion, 12 genes were selected for further study of their expression
in invasive pancreatic cancer tissues by in situ
hybridization (Table 1)
. These gene
expression markers were selected to represent different categories of
biochemical function, such as cellular growth factors (connective
tissue growth factor), signal transduction (ß-catenin), cellular
adhesion (ß-catenin, intercellular adhesion molecule-1),
extracellular matrix remodeling (matrix metalloproteinases 2, 11, and
14), and markers of specific cell or tissue types (ie, hevin,
endothelium and thrombospondin-1, extracellular
matrix).9-15
In addition, four genes were chosen from the
invasion-associated gene cluster whose role is currently unknown in
neoplasia (apolipoprotein C-1, apolipoprotein D, 
-2 macroglobulin,
and -2 macroglobulin receptor).16,17
Two classes of
genes were excluded from study: those whose expression represented
normal parenchymal markers of the pancreas (for example, insulin), and
those that were presumed markers of the immune response (immunoglobulin
genes).
|
In situ hybridization was performed for each of the 12 invasive tissue-specific genes on two samples of fresh frozen tissue obtained from pancreaticoduodenectomy specimens removed for infiltrating adenocarcinoma of the pancreas. One sample was from a 79-year-old woman with a poorly differentiated infiltrating duct carcinoma, and the other sample was from a 49-year-old woman with a moderate to poorly differentiated infiltrating duct carcinoma. Neither tumor had a medullary histological pattern.18
Detectable expression of all 12 genes were observed in both neoplasms,
localized as precipitated Fast Red chromagen. For each gene, detectable
expression was found to localize to one or more of four distinct
architectural regions, or gene expression compartments, of the invasive
tumors: 1) neoplastic epithelium, 2) angioendothelium and/or vascular
smooth muscle, 3) juxtatumoral stroma (ie, only those stromal cells
immediately adjacent to the invasive neoplastic
epithelium), or to 4) panstromal tissue (ie, all stromal tissue of the
invasive tumor) (Figure 1)
.
|
. Expression of CTGF, ICAM-1,
ß-catenin, and MMP14 were all localized to neoplastic epithelium,
with no additional expression noted in the surrounding stromal or
angioendothelial compartments. In contrast, hevin expression was noted
only within endothelial cells of small capillaries and venules, and in
scattered smooth muscle cells of small arterioles within the mass of
the invasive tumor. No expression of hevin was found within the
neoplastic epithelium or in stromal cells of the desmoplastic response.
With respect to apolipoprotein C-1, apolipoprotein D, and MMP11, gene
expression was observed primarily in the juxtatumoral stroma, whereas
the neoplastic epithelial and angioendothelial compartments were
negative for expression of these genes.
|
-2 macroglobulin expression was localized
to endothelial cells and juxtatumoral stroma. In contrast, -2
macroglobulin receptor and thrombospondin-1 both
demonstrated gene expression within both the neoplastic epithelium and
the panstromal compartments. Only endothelial cells and vascular
structures were negative for expression of -2 macroglobulin receptor
and thrombospondin-1. MMP2 gene expression was localized to the
panstromal compartment of the tumors, as well as to angioendothelium
and vascular smooth muscle of small arterioles. Neoplastic epithelium
was negative for expression of MMP2.
Focal expression of some genes was also noted in atrophic pancreatic
parenchyma adjacent to the tumor mass, suggestive of epithelial-stromal
interactions that also exist within the nonneoplastic pancreas. For
example, CTGF, ß-catenin, and ICAM-1 were detected in scattered
atrophic pancreatic ducts, whereas apolipoprotein D, MMP2, and -2
macroglobulin expression was observed in stromal cells within lobules
of acinar cells undergoing atrophy adjacent to the invasive tumor.
Alpha-2 macroglobulin receptor expression was detected in both atrophic
ducts and stroma within areas of lobular atrophy. As expected, hevin
and thrombospondin-1 were expressed in angioendothelial tissues in
nonneoplastic pancreas.
Expression of Apolipoprotein D and MMP2 in Archival Samples of Pancreatic Carcinoma
To confirm our observations of distinct compartments of gene expression, we studied a separate set of invasive ductal adenocarcinomas of the pancreas, a series of paraffin-embedded specimens obtained from the files of The Johns Hopkins Hospital. The genes chosen for this confirmation were apolipoprotein D and MMP2, which were found in our initial observations to be expressed in different architectural compartments of gene expression within the host stromal response to invasive pancreatic carcinoma.
In situ hybridization was performed for both genes on six
samples of paraffin-embedded invasive pancreatic carcinoma (Figure 3)
. In situ hybridization of
apolipoprotein D demonstrated tissue labeling in four of six cases
(66%). In all four positive cases, mRNA expression of apolipoprotein D
was localized to the juxtatumoral stroma, as well as to small nerves
within the pancreatic parenchyma. MMP2 mRNA expression was also
observed in four of six cases (66%). In contrast to apolipoprotein D,
MMP2 expression was localized to the entire host stromal response,
including the endothelium of small arterioles.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
Our findings demonstrate that the genes found to be overexpressed in SAGE libraries are indeed overexpressed in tissues. Of the 12 genes selected from 74 invasion-specific genes identified, all were found to be highly expressed in samples of invasive carcinoma. Unexpectedly, four (CTGF, ICAM-1, ß-catenin, and MMP14) showed expression localized to the neoplastic epithelium in all cases wherein the transcripts were detectable. The expression of these four genes in the epithelium of invasive pancreatic cancers, but not in passaged cancer cell lines derived from pancreas cancer, may indicate that important differences exist in the gene expression profiles of in vivo and in vitro systems of carcinoma cells. Of the remaining eight genes studied, none were expressed by neoplastic epithelium, but rather were localized to either angioendothelial cells within the tumor mass, or instead to the stromal elements of the tumor. The expression of these genes in samples of primary pancreatic carcinoma, but not in passaged cell lines of pancreatic carcinoma, is now rationalized as reflecting the presence of stromal elements in the primary specimens. Thus, these genes represent markers of the host reaction to the neoplasm.
The use of 12 different markers of invasive tissue-specific gene expression helped define a transcriptomic architecture of an invasive cancer. Indeed, the presence of a marked desmoplastic host response within invasive pancreatic cancer allows for a facile determination and mapping of these various architectural compartments that might be more difficult to discern in other tumor types. Four different compartments were identified based on the regions of positive gene expression, which we describe as neoplastic epithelium, angioendothelial, panstromal, and juxtatumoral stroma—a specialized region of the stroma immediately adjacent to the invasive tumor epithelium. These distinct and reproducible compartments of gene expression of the invasive tissue-specific genes indicate a highly organized, structured, and coordinated process of tumor invasion in the pancreas.
Our data also indicate that these compartments are not segregated
from each other; rather, the data suggest potential lines of
communication between different compartments of the invasive tumor. For
example, we found -2 macroglobulin to be expressed by juxtatumoral
stroma, whereas the receptor for this gene product, -2 macroglobulin
receptor, is expressed by the neoplastic epithelium. Alpha-2
macroglobulin has been suggested to act as a growth factor in malignant
cells expressing -2 macroglobulin receptor.17
Thus, the
juxtatumoral stroma (to at least some extent in that it involves highly
expressed genes) may represent an active participant in the invasive
process that may signal to the invading neoplastic epithelium. Such
models have been suggested in the past, but had not been derived from
unbiased surveys of gene expression.25,26
Conversely, we
have shown that MMP14, a membrane-bound metalloproteinase, is expressed
by neoplastic epithelium, whereas MMP2, a known substrate of MMP14, is
expressed by the surrounding stroma. If MMP14 were to proteolytically
cleave proMMP2, MMP2 would be activated in sites within the stroma to
promote neoplastic cell invasion.
The identification of several lipocalins as invasive tissue-specific gene markers in invasive pancreatic cancer sheds new light on this gene family with a potentially important and unrecognized role in the process of tumor invasion. Lipocalins have been identified in other studies of gene expression as determined by SAGE.24 The function of lipocalins is not well understood, but they seem to play a role in lipid homeostasis.16 Thus, their expression by juxtatumoral stroma in invasive pancreatic cancer, to provide one suggestion, may indicate a role for lipid metabolism that could serve to supplement and provide a nutritive role by the juxtatumoral stroma for the tumor epithelium. At the least, the analysis of architectural compartments serves well to generate hypotheses that would be otherwise not considered.
In summary, our finding of distinct architectural compartments of gene expression in invasive cancer, and particularly within the desmoplastic response, provides new insight into the host response to invasive cancer. The regional gene expression of the host response, together with the finding of possible communication between the stroma and invasive neoplastic epithelium, suggests that the host response plays an active role in promoting invasiveness of the neoplastic epithelium. The biological nature of juxtatumoral stroma needs exploration, separate from the panstromal compartment. Further studies to understand the biology of this desmoplastic response to invasive neoplasms may aid in identifying new targets for clinical imaging, serological diagnosis, drug development, and delivery.
|
Note added in Proof |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
|
Footnotes |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
Supported by the National Institutes of Health Specialized Programs of Research Excellence in Gastrointestinal Cancer grant CA62924.
Accepted for publication September 19, 2001.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionNote added in ProofReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  B. Zhong, P. Strnad, D. M. Toivola, G.-Z. Tao, X. Ji, H. B. Greenberg, and M. B. Omary Reg-II Is an Exocrine Pancreas Injury-Response Product That Is Up-Regulated by Keratin Absence or Mutation Mol. Biol. Cell, December 1, 2007; 18(12): 4969 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mahadevan and D. D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Sneddon, H. H. Zhen, K. Montgomery, M. van de Rijn, A. D. Tward, R. West, H. Gladstone, H. Y. Chang, G. S. Morganroth, A. E. Oro, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation PNAS, October 3, 2006; 103(40): 14842 - 14847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Ottaviano, L. Sun, V. Ananthanarayanan, and H. G. Munshi Extracellular Matrix-Mediated Membrane-Type 1 Matrix Metalloproteinase Expression in Pancreatic Ductal Cells Is Regulated by Transforming Growth Factor-{beta}1. Cancer Res., July 15, 2006; 66(14): 7032 - 7040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dornhofer, S. Spong, K. Bennewith, A. Salim, S. Klaus, N. Kambham, C. Wong, F. Kaper, P. Sutphin, R. Nacalumi, et al. Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., June 1, 2006; 66(11): 5816 - 5827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aikawa, J. Gunn, S. M. Spong, S. J. Klaus, and M. Korc Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1108 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. White, H. B. Xie, M. R. Gottfried, B. G. Czito, H. I. Hurwitz, M. A. Morse, G. C. Blobe, E. K. Paulson, J. Baillie, M. S. Branch, et al. Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer Ann. Surg. Oncol., March 1, 2005; 12(3): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sato, N. Maehara, and M. Goggins Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts Cancer Res., October 1, 2004; 64(19): 6950 - 6956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. West, C. L. Corless, X. Chen, B. P. Rubin, S. Subramanian, K. Montgomery, S. Zhu, C. A. Ball, T. O. Nielsen, R. Patel, et al. The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status Am. J. Pathol., July 1, 2004; 165(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Brekken, M. M. Sullivan, G. Workman, A. D. Bradshaw, J. Carbon, A. Siadak, C. Murri, P. E. Framson, and E. H. Sage Expression and Characterization of Murine Hevin (SC1), a Member of the SPARC Family of Matricellular Proteins J. Histochem. Cytochem., June 1, 2004; 52(6): 735 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Esposito, M Menicagli, N Funel, F Bergmann, U Boggi, F Mosca, G Bevilacqua, and D Campani Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma J. Clin. Pathol., June 1, 2004; 57(6): 630 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
S. Muerkoster, K. Wegehenkel, A. Arlt, M. Witt, B. Sipos, M.-L. Kruse, T. Sebens, G. Kloppel, H. Kalthoff, U. R. Folsch, et al. Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1{beta} Cancer Res., February 15, 2004; 64(4): 1331 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, Z. Zhang, N. White, J. Rosenzweig, N. Fedarko, S. Jagannath, M. I. Canto, C. J. Yeo, D. W. Chan, and M. Goggins Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry Clin. Cancer Res., February 1, 2004; 10(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al. Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies Cancer Res., December 15, 2003; 63(24): 8614 - 8622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hansel, A. Rahman, M. Hidalgo, P. J. Thuluvath, K. D. Lillemoe, R. Shulick, J.-L. Ku, J.-G. Park, K. Miyazaki, R. Ashfaq, et al. Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology Am. J. Pathol., July 1, 2003; 163(1): 217 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Cheng and L. M. Weiner Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin. Cancer Res., May 1, 2003; 9(5): 1590 - 1595. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen, A. W. Lowe, N. T. Van Heek, C. Rosty, K. Walter, N. Sato, A. Parker, R. Ashfaq, et al. Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays Am. J. Pathol., April 1, 2003; 162(4): 1151 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sato, N. Maehara, G. H. Su, and M. Goggins Effects of 5-Aza-2'-deoxycytidine on Matrix Metalloproteinase Expression and Pancreatic Cancer Cell Invasiveness J Natl Cancer Inst, February 19, 2003; 95(4): 327 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, P. Argani, P. M. Hempen, J. Jones, and S. E. Kern The Desmoplastic Response to Infiltrating Breast Carcinoma: Gene Expression at the Site of Primary Invasion and Implications for Comparisons between Tumor Types Cancer Res., September 15, 2002; 62(18): 5351 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, A. Maitra, G. L. Shen-Ong, T. van Heek, R. Ashfaq, R. Meyer, K. Walter, K. Berg, M. A. Hollingsworth, J. L. Cameron, et al. Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology Am. J. Pathol., April 1, 2002; 160(4): 1239 - 1249. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
